Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric M Ruderman

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
ACR Open Rheumatology|December 28, 2021
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle StudyMaria I Danila, Lang Chen, Eric M Ruderman, et al.
Rheumatology (Oxford, England)|December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisPeter Nash, Pascal Richette, Laure Gossec, et al.
European Journal of Immunology|February 4, 2009
The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophagesJohn C Scatizzi, Melissa Mavers, Jack Hutcheson, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Inflammatory Bowel Diseases|August 31, 2021
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNAAnne Grosen, Emanuelle Bellaguarda, Jacob Nersting, et al.
Arthritis Care & Research|May 26, 2017
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid ArthritisLeslie R Harrold, George W Reed, Ani John, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
Journal of the American Medical Informatics Association : JAMIA|March 1, 2012
Portability of an algorithm to identify rheumatoid arthritis in electronic health recordsRobert J Carroll, Will K Thompson, Anne E Eyler, et al.
The Journal of Rheumatology|December 25, 2009
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 StudyPhilip J Mease, Nathan Wei, Edward J Fudman, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
ACR Open Rheumatology|December 28, 2021
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle StudyMaria I Danila, Lang Chen, Eric M Ruderman, et al.
Rheumatology (Oxford, England)|December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisPeter Nash, Pascal Richette, Laure Gossec, et al.
European Journal of Immunology|February 4, 2009
The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophagesJohn C Scatizzi, Melissa Mavers, Jack Hutcheson, et al.
Arthritis and Rheumatism|October 4, 2005
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialPhilip J Mease, Dafna D Gladman, Christopher T Ritchlin, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Inflammatory Bowel Diseases|August 31, 2021
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNAAnne Grosen, Emanuelle Bellaguarda, Jacob Nersting, et al.
Arthritis Care & Research|May 26, 2017
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid ArthritisLeslie R Harrold, George W Reed, Ani John, et al.
Rheumatology and Therapy|November 17, 2020
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H StudyJosef S Smolen, Anthony Sebba, Eric M Ruderman, et al.
Journal of the American Medical Informatics Association : JAMIA|March 1, 2012
Portability of an algorithm to identify rheumatoid arthritis in electronic health recordsRobert J Carroll, Will K Thompson, Anne E Eyler, et al.
The Journal of Rheumatology|December 25, 2009
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 StudyPhilip J Mease, Nathan Wei, Edward J Fudman, et al.
Pageof 7